Spyre Therapeutics (SYRE) Accumulated Expenses (2015 - 2026)

Spyre Therapeutics has reported Accumulated Expenses for 12 years, with the latest figure at $29.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 34.81% year-over-year to $29.2 million; the trailing twelve-month figure through Mar 2026 stood at $29.2 million (up 34.81% YoY), and the FY2025 full-year result was $26.9 million, down 2.76% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $29.2 million, up from $26.9 million in the prior quarter.
• The five-year high for Accumulated Expenses was $29.2 million in Q1 2026, with the low at $2.4 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $17.5 million across 5 years, with a median of $15.9 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 353.12% — and 2024, when it tumbled 80.01%.
• Spyre Therapeutics' Accumulated Expenses stood at $12.8 million in 2022, then gained by 2.11% to $13.1 million in 2023, then surged by 111.41% to $27.7 million in 2024, then retreated by 2.76% to $26.9 million in 2025, then climbed by 8.21% to $29.2 million in 2026.
• The last three Accumulated Expenses figures came in at $29.2 million (Q1 2026), $26.9 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.